
Brainsway Ltd. Net Debt | BWAY
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Brainsway Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -63.7 M | -10 M | -47.1 M | - | - | - | -6.88 M | -11.8 M | -8.36 M | -11.4 M | -17.3 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -6.88 M | -63.7 M | -22.1 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Diagnostics research industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Enzo Biochem
ENZ
|
-51.3 M | - | -8.98 % | $ 14.8 K | ||
|
QIAGEN N.V.
QGEN
|
1.31 B | - | - | $ 10.6 B | ||
|
Centogene N.V.
CNTG
|
-4.52 M | - | -6.23 % | $ 30.6 M | ||
|
Charles River Laboratories International
CRL
|
1.98 B | $ 288.5 | 0.54 % | $ 14.3 B | ||
|
Aspira Women's Health
AWH
|
-512 K | - | -6.19 % | $ 10.5 M | ||
|
DarioHealth Corp.
DRIO
|
9.37 M | $ 7.24 | 3.72 % | $ 28.8 M | ||
|
Celcuity
CELC
|
-28.1 M | $ 95.7 | 0.44 % | $ 4.47 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
-173 M | - | - | $ 562 M | ||
|
Check-Cap Ltd.
CHEK
|
-3.13 M | - | - | $ 9.42 M | ||
|
Akumin
AKU
|
1.21 B | - | -17.87 % | $ 25.9 M | ||
|
Accelerate Diagnostics
AXDX
|
-14.5 M | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
-11.2 M | - | -13.05 % | $ 7.29 M | ||
|
Global Cord Blood Corporation
CO
|
-6.07 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
-5.38 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-789 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-135 M | - | 0.12 % | $ 80.1 M | ||
|
Chembio Diagnostics
CEMI
|
-17.2 M | - | 0.22 % | $ 16.8 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
769 M | - | - | $ 10.7 B | ||
|
DermTech
DMTK
|
-33.6 M | - | -11.32 % | $ 2.94 M | ||
|
Quest Diagnostics Incorporated
DGX
|
4.92 B | $ 237.14 | 2.07 % | $ 26.3 B | ||
|
DexCom
DXCM
|
-842 M | $ 87.9 | 0.02 % | $ 34.3 B | ||
|
Heska Corporation
HSKA
|
-153 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-11.2 M | - | -20.0 % | $ 1.06 M | ||
|
ICON Public Limited Company
ICLR
|
2.26 B | $ 164.85 | 0.78 % | $ 12.9 B | ||
|
Soleno Therapeutics
SLNO
|
-19.5 M | - | - | $ 2.69 B | ||
|
Psychemedics Corporation
PMD
|
-912 K | - | -1.84 % | $ 15.3 M | ||
|
Motus GI Holdings
MOTS
|
-3.55 M | - | -34.28 % | $ 263 K | ||
|
Syneos Health
SYNH
|
2.54 B | - | - | $ 4.46 B | ||
|
Laboratory Corporation of America Holdings
LH
|
4.74 B | $ 326.89 | 0.29 % | $ 27.2 B | ||
|
Invitae Corporation
NVTA
|
-239 M | - | - | $ 21.2 M | ||
|
Organovo Holdings
ONVO
|
-10.4 M | - | -2.3 % | $ 19.4 M | ||
|
OpGen
OPGN
|
1.32 M | - | -16.95 % | $ 1.54 M | ||
|
T2 Biosystems
TTOO
|
-7.48 M | - | -39.35 % | $ 313 K | ||
|
Anixa Biosciences
ANIX
|
-1.04 M | $ 3.07 | 0.66 % | $ 99.6 K | ||
|
PerkinElmer
PKI
|
2.3 B | - | -0.91 % | $ 14.7 B | ||
|
Meridian Bioscience
VIVO
|
-54.6 M | - | - | $ 1.49 B | ||
|
Quotient Limited
QTNT
|
172 M | - | -11.32 % | $ 1.1 M | ||
|
Mettler-Toledo International
MTD
|
2.06 B | $ 1 345.26 | 0.11 % | $ 27.7 B | ||
|
Myriad Genetics
MYGN
|
-22.8 M | $ 3.18 | 1.57 % | $ 294 M | ||
|
ENDRA Life Sciences
NDRA
|
-270 K | $ 6.05 | 6.51 % | $ 4.76 M | ||
|
National Research Corporation
NRC
|
71.3 M | $ 21.53 | 1.32 % | $ 482 M | ||
|
Renalytix AI plc
RNLX
|
-24.5 M | - | 5.66 % | $ 22.7 M | ||
|
Interpace Biosciences
IDXG
|
-1.32 M | $ 1.45 | 2.11 % | $ 6.41 M | ||
|
OPKO Health
OPK
|
-351 M | $ 1.64 | 1.86 % | $ 1.23 B | ||
|
Pacific Biosciences of California
PACB
|
-6.67 M | $ 1.35 | 3.85 % | $ 405 M | ||
|
IQVIA Holdings
IQV
|
12 B | $ 267.77 | 2.95 % | $ 46 B | ||
|
Surmodics
SRDX
|
-5.52 M | - | - | $ 608 M | ||
|
Personalis
PSNL
|
-117 M | $ 17.2 | 2.2 % | $ 1.53 B | ||
|
Quidel Corporation
QDEL
|
-377 M | $ 13.97 | 0.29 % | $ 588 M |